Piramal Pharma Limited has announced that a meeting of the Board of Directors is scheduled for January 28, 2026. The board will review and approve the unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2025. The company also announced the closure of the ‘Trading Window’ for dealing in the company’s securities which will remain closed until January 30, 2026.
Board Meeting Announcement
Piramal Pharma Limited has scheduled a meeting of its Board of Directors to be held on January 28, 2026. During this meeting, the board will consider and approve the company’s unaudited financial results.
Financial Results Discussion
The board will specifically review the unaudited financial results, both standalone and consolidated, for the quarter and nine-month period ending December 31, 2025 (Q3).
Trading Window Closure
The company has also announced the closure of its ‘Trading Window’. This closure, which began on January 1, 2026, will remain in effect through January 30, 2026. This restriction affects those dealing in the securities of Piramal Pharma.
Source: BSE
